Akari Therapeutics
AKTX
10 hedge funds and large institutions have $3.88M invested in Akari Therapeutics in 2018 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
11% more funds holding
Funds holding: 9 → 10 (+1)
0% less ownership
Funds ownership: 0% → 0% (-0%)
2% less capital invested
Capital invested by funds: $3.97M → $3.88M (-$96K)
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HP
Hikari Power
Tokyo,
Japan
|
+$408K |
| 2 |
VF
Virtu Financial
New York
|
+$58.1K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$6.28K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$553K |
| 2 |
Millennium Management
New York
|
-$265K |
| 3 |
ECM
Endurant Capital Management
San Mateo,
California
|
-$34.6K |
| 4 |
IA
IFP Advisors
Tampa,
Florida
|
-$4K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
HP
1
Hikari Power
Tokyo,
Japan
| $1.65M | +$408K | +260 | +33% |
|
|
NMC
2
NEA Management Company
Timonium,
Maryland
| $882K | – | – | – |
|
|
VC
3
Vivo Capital
Palo Alto,
California
| $674K | – | – | – |
|
|
ECM
4
Endurant Capital Management
San Mateo,
California
| $352K | -$34.6K | -22 | -9% |
|
|
BBA
5
Baker Bros. Advisors
New York
| $115K | -$553K | -352 | -83% |
|
|
6
Millennium Management
New York
| $69K | -$265K | -169 | -79% |
|
7
Bank of Montreal
Toronto,
Ontario, Canada
| $59K | – | – | – |
|
|
VF
8
Virtu Financial
New York
| $58K | +$58.1K | +37 | New |
|
9
Parallax Volatility Advisers
San Francisco,
California
| $15K | – | – | – |
|
|
10
UBS Group
Zurich,
Switzerland
| $5K | +$6.28K | +4 | New |
|
|
IA
11
IFP Advisors
Tampa,
Florida
| – | -$4K | -1 | Closed |
|
AKTX Hedge Fund Activity: Q2 2018 in Review
10 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in Akari Therapeutics (AKTX) for Q2 2018, worth a combined $3.88M — down 2.4% from $3.97M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new AKTX positions and 1 closed out — a net gain of 1 holder — while 1 added to existing stakes and 3 trimmed.
The largest buyer was Hikari Power, adding an estimated $408K. The largest seller was Baker Bros. Advisors, cutting an estimated $553K.
- 10 institutional investors held Akari Therapeutics (AKTX) as of Q2 2018, up from 9 in Q1 2018.
- Funds reported $3.88M of Akari Therapeutics stock for Q2 2018, down 2.4% quarter-over-quarter.
- 2 funds opened new Akari Therapeutics positions in Q2 2018 and 1 closed out, a net change of +1 holder.
- The largest Akari Therapeutics buyer in Q2 2018 was Hikari Power, an estimated $408K added.
- The largest Akari Therapeutics seller in Q2 2018 was Baker Bros. Advisors, an estimated $553K sold.
Based on aggregated 13F filings for Q2 2018.